Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 1, 2007

Primary Completion Date

June 5, 2014

Study Completion Date

July 9, 2018

Conditions
Lung Cancer
Interventions
RADIATION

Boost Stereotactic Body Radiation Therapy

"The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy."

Trial Locations (1)

40536

Markey Cancer Center, Lexington

All Listed Sponsors
lead

Ronald McGarry

OTHER

NCT01657617 - Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter